Send Message
ANHUI BBCA PHARMACEUTICAL CO.,LTD
ANHUI BBCA PHARMACEUTICAL CO.,LTD
products
Home /

products

GMP Certified Levofloxacin Hydrochloride Capsules Treat Infections

Product Details

Certification: GMP

Model Number: BBCA18011527

Payment & Shipping Terms

Price: Negotiated

Packaging Details: 10CapsulesX200Boxes/Carton

Delivery Time: 25 DAYS AFTER PAYMENT

Payment Terms: L/C, T/T, , MoneyGram, L/C, T/T, , MoneyGram

Get Best Price
Contact Now
Specifications
Highlight:

antibacterial medication

,

azithromycin capsules

Place Of Origin:
China (Mainland)
Brand Name:
BBCA
Other Names:
GMP Certified Levofloxacin Hydrochloride Capsules
Grade:
Medicine Grade
Dosage Form:
Injection
Place Of Origin:
China (Mainland)
Brand Name:
BBCA
Other Names:
GMP Certified Levofloxacin Hydrochloride Capsules
Grade:
Medicine Grade
Dosage Form:
Injection
Description
GMP Certified Levofloxacin Hydrochloride Capsules Treat Infections

GMP Certified Levofloxacin Hydrochloride Capsules Treat Infections

 

Specifications

 

Levofloxacin Hydrochloride Capsules

Type: Synthesized antimicrobial agents

Usage: Anti-infection

Packing: 10CapsulesX200Boxes/Carton

GMP Certified

Standard: 0.1g ;CP, USP, BP

Original: China

Manufacture: ANHUI BBCA PHARMRACEUTICAL Co., Ltd.

 

Levofloxacin is used to treat infections including: respiratory tract infections, cellulitis, urinary tract infections, prostatitis, anthrax, endocarditis, meningitis, pelvic inflammatory disease, traveler's diarrhea, tuberculosis, and plague and is available by mouth, intravenously,and in eye drop form.

Levofloxacin and other fluoroquinolones have also been widely used for the treatment of uncomplicated community-acquired respiratory and urinary tract infections, indications for which major medical societies generally recommend the use of older, narrower spectrum drugs to avoid fluoroquinolone resistance development. Due to its widespread use, common pathogens such as Escherichia coli and Klebsiella pneumoniae have developed resistance. In many countries as of 2013, resistance rates among healthcare-associated infections with these pathogens exceeded 20%.

 

Send your inquiry
Please send us your request and we will reply to you as soon as possible.
Send